On October 19, 2026 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, reported investors and the scientific community that clinical and preclinical data for ATNM-400 will be presented today at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM), being held October 17–21, 2026, in Vienna, Austria.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The clinical oral presentation will feature early data from the ongoing first-in-human Phase 1 dose-escalation study of ATNM-400 in metastatic castration-resistant prostate cancer (mCRPC). It will describe evaluation of the Zirconium-89-labeled imaging counterpart, including safety, biodistribution, dosimetry and serial PET assessment of tumor uptake and clearance, to inform development and dosing of Actinium-225-labeled ATNM-400.
The preclinical oral presentation will feature studies of ATNM-400 in KRAS- and ALK-driven non-small cell lung cancer (NSCLC) models, including evaluation as monotherapy and in combination with KRAS or ALK inhibitors. The presentation builds on earlier EGFR-mutant research and will discuss the rationale for mutation-agnostic development across lung cancer subtypes.
ATNM-400 is an investigational, first-in-class Actinium-225 antibody radioconjugate targeting HER3. The program is being developed to expand targeted radiotherapy beyond PSMA in prostate cancer and explore its potential across multiple solid tumors, as a monotherapy and in combination with established treatments.
EANM 2026 Presentation Details
Both sessions: Monday, October 19, 2026, 4:45–6:15 p.m. CEST (10:45 a.m.–12:15 p.m. EDT).
Clinical prostate cancer presentation | OP-525
First-in-human Phase 1 study of ATNM-400 in mCRPC
Session 1111: Theranostics Track: Prostate Cancer Therapy II | Hall G1
Preclinical lung cancer presentation | EPS-149
ATNM-400 in KRAS- and ALK-driven NSCLC models
Session 1109: Translational Imaging and Therapy | Hall G2
(Press release, Actinium Pharmaceuticals, OCT 19, 2026, View Source [SID1234673551])